Checkpoint Therapeutics Inc (CKPT) Stock Price, Quote & News

Company Profile

Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignanci...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Fax: 646 619 4950

Website: checkpointtx.com

Address:

95 Sawyer Road, Suite 110, Waltham, United States

jjangles123 Aug. 7 at 6:30 PM

$MIST Another pattern, $CKPT had CRL, steep drop, announced offering, a drop. Then the run up that resulted in PDUFA acceptance Dec 2024 doubled. Which is exactly where we are right now.

0 · Reply

Zellchair Aug. 5 at 4:03 PM

$FBIO $FBIOP $CKPT Read the last paragraph here if you want a little more detail about why Checkpoint first received its CRL from the FDA. https://www.fiercepharma.com/pharma/weak-evidence-and-unpleasant-odors-fda-sheds-light-drug-refusal-process

0 · Reply

Zellchair Aug. 4 at 10:01 PM

$FBIO $FBIOP $CKPT "Unloxcyt would have some prescriber overlap with Odomzo" https://www.icicidirect.com/mailcontent/idirect_sunpharma_q1fy26.pdf

0 · Reply

Zellchair Aug. 4 at 1:24 PM

$FBIO $FBIOP $CKPT If you want to learn more about ODOMZO (marketed in US, Canada, EU, Australia and Israel) to get an idea of these potential sales synergies, I recommend you start with these sources: Official homepage: https://www.odomzo.com/ Latest Annual Report: https://sunpharma.com/wp-content/uploads/2025/07/SPIL-Annual-Report-2024-25.pdf Latest Investor Presentation: https://sunpharma.com/wp-content/uploads/2025/07/SPIL-IR-Presentation-July-2025-INR.pdf

0 · Reply

Zellchair Aug. 4 at 1:19 PM

$FBIO $FBIOP $CKPT I have previously written on Substack that Sun Pharma would invest $100M in the launch of UNLOXCYT and Leqselvi. Since Leqselvi was already launch in this context/time of that news and that it belongs to Sun's established dermatology business segment, I conclude that a majority of the $100M will go to the UNLOXCYT launch. During CC last week, Sun's management also confirmed that $100M was only in the first stage. Another reason why I believe that Sun Pharma has good conditions for a launch, besides the label news that I released last week, is Suns existing drug ODOMZO where they already have an established sales team not only in Oncology but also a variant of skin cancer. I looked today at 4 previous job advertisements for Sun in the US (Orange Co, Riverside, Fort Lauderdale, Richmond) and all of them include commercialization of only ODOMZO and UNLOXCYT. I think this confirms that the already established ODOMZO sales team will also include UNLOXCYT.

0 · Reply

Zellchair Aug. 3 at 1:20 PM

$FBIO $DERM $CKPT $MBIO Fortress Biotech Pref FBIOP (special situation) - Substack 7-8 Part 7 - Fortress Biotech FBIOP - AstraZeneca's Q2 gives renewed real hope for CAEL-101 plus more news regarding Triplex, Dotinurad, UNLOCXYT & Journey Medical https://zellchair.substack.com/p/fortress-biotech-fbiop-astrazenecas Part 8 - Fortress Biotech – New major revelations about Crystalys (Dotinurad), UNLOXCYT launch & Triplex “competitors” Q1 sales https://zellchair.substack.com/p/fortress-biotech-new-major-revelations $XBI

1 · Reply

Zellchair Aug. 1 at 1:17 PM

$FBIO $FBIOP Part 8: Fortress Biotech – New major revelations about Crystalys (Dotinurad), UNLOXCYT launch $CKPT & Triplex “competitors” Q1 sales $TAK $MRNA Several significant updates followed by own position update in FBIO & FBIOP https://zellchair.substack.com/p/fortress-biotech-new-major-revelations

0 · Reply

TwongStocks Jul. 30 at 1:05 PM

$CKPT For everyone asking about updates. The best place to get updates is from Sun Pharma. Unfortunately, they aren't traded in the US, so no SEC filings. But you can view their press releases here: https://sunpharma.com/media/ The big thing to pay attention to is when they announce positive validation of the MAA for UNLOXCYT. That starts the clock. To get the $0.70 payout, UNLOXCYT needs to be approved within 2 years of positive MAA validation at an approved dose of once very 3 weeks (see chart). Per the agreement, Sun has to submit UNLOXCYT's MAA in Europe by May 30, 2026. After it is submitted, they have to wait for it to be validated before the EMA starts the approval process.

0 · Reply

Zellchair Jul. 27 at 7:04 AM

$FBIO $FBIOP Regarding my answers about insiders here earlier. Weiss' shares in $TGTX are worth about $520M right now and the stock is still a good distance from ATH. $10B in market cap (far from impossible) plus the bonus and his shares/bonus pass $900M. And if you don't believe he is highly involved in everything that happens at Fortress and all its subsidiaries read the "PRELIMINARY PROXY STATEMENT — SUBJECT TO COMPLETION, DATED APRIL 14, 2025", from the deal between $CKPT and Sun.

1 · Reply

Zellchair Jul. 26 at 10:51 AM

$FBIO $FBIOP $DERM $CKPT $MBIO Fortress Biotech Pref FBIO (special situation) - Substack 1-6 – Resumed dividends can create significant value for shareholders in the form of accumulated dividends and significantly increasing in share price Part 1 - Fortress Biotech Preferred FBIOP (5 May) https://zellchair.substack.com/p/fortress-biotech-preferred-fbiop Part 2 - Fortress Biotech – News since first published Substack-post about FBIOP (2 July) https://zellchair.substack.com/p/fortress-biotech-news-since-first Part 3 - Fortress Biotech – The numbers that describe the uniqueness behind the company (7 July) https://zellchair.substack.com/p/fortress-biotech-the-numbers-that Part 4 - Fortress Biotech - Sold shares in FBIOP after CAEL-101 fails to reach primary endpoint in P3 (18 July) https://zellchair.substack.com/p/fortress-biotech-sold-shares-in-fbiop Part 5 - Fortress Biotech - New all-time high in FBIOP shares & size in the stock portfolio (24 July) https://zellchair.substack.com/p/fortress-biotech-new-all-time-high Part 6 - Fortress Biotech – Update regarding CAEL-101 announcement, EMROSI, CUTX-101 news & Dotinurad, Triplex potential strategic options in the future (25 July) https://zellchair.substack.com/p/fortress-biotech-update-regarding

1 · Reply

Market Cap	370.71M
Revenue (ttm)	40,000.00
Net Income (ttm)	-56.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-140,600.01%
Debt to Equity Ratio	0.00

Volume	8,666,800
Avg Vol	1,808,080
Day's Range	N/A - N/A
Shares Out	87.02M
Stochastic %K	85%
Beta	1.18
Analysts	Sell
Price Target	$4.45